4D Molecular Therapeutics Inc (NAS:FDMT)
$ 25.15 0 (0%) Market Cap: 1.30 Bil Enterprise Value: 788.60 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 57/100

4D Molecular Therapeutics Inc 4D-150 Phase 1/2 PRISM Interim Clinical Data - Corporate Call Transcript

Apr 27, 2023 / 12:00PM GMT
Release Date Price: $16.5 (-19.79%)
Operator

Hello, ladies and gentlemen. Thank you for standing by, and welcome to 4D Molecular Therapeutics webcast presentation of interim safety and efficacy data from the Phase I/II PRISM clinical trial of intravitreal 4D-150 in patients with wet age-related macular degeneration. (Operator Instructions) As a reminder, today's call is being recorded.

With that, I will hand the call over to August Moretti, Chief Financial Officer, who will make introductory comments.

August J. Moretti
4D Molecular Therapeutics, Inc. - CFO

Thank you, operator, and welcome, everyone, to 4D Molecular Therapeutics 4D-150 interim data webcast. A press release describing the results and development plans related to 4D-150 is accessible in the Investors section of the 4D Molecular Therapeutics website, and a recording of this webcast will be accessible on our website after completion of this call.

With me today are Dr. David Kirn, our Co-Founder and Chief Executive Officer; Dr. Bob Kim, our Chief Medical Officer; and Dr. Arshad Khanani, Managing Partner and Director of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot